{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:22:55Z","timestamp":1783466575856,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01DE029188"],"award-info":[{"award-number":["U01DE029188"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA190294"],"award-info":[{"award-number":["R01CA190294"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>cGAS-STING signaling can promote antitumor immunity, and tumor cell STING is suppressed in a variety of cancer subtypes that resist immune checkpoint blockade. Although STING agonists have failed clinical trials, precision approaches targeting restoration of tumor cell STING expression have yet to be explored. Here, we report that head and neck squamous cell cancer (HNSCC) exhibits a mechanism of STING suppression related to upregulation of protein tyrosine phosphatase non-receptor (PTPN) type 2 (PTPN2) that is also evident in other cancers. PTPN2 inhibition (PTPN2i) increases HNSCC tumor cell STING by restoring IFN\u03b3-STAT1\u2013mediated induction of STING mRNA. This restores sensitivity to STING agonism and natural killer cell activation, suppressing tumor growth in an immune cell-dependent manner in anti-PD-1 refractory syngeneic HNSCC mouse tumor models in female mice. Together, these findings demonstrate that PTPN2i can unleash STING agonist response, providing a rationale for the evaluation of this therapeutic combination in HNSCC and potentially other cancer types.<\/jats:p>","DOI":"10.1038\/s41467-026-72372-1","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:24:40Z","timestamp":1777724680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-3324","authenticated-orcid":false,"given":"Zehua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4391-6943","authenticated-orcid":false,"given":"Kartik","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Egloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran C.","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Avila","family":"Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cun Lan","family":"Chuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaiza","family":"Senent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia Shea","family":"Lineberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin K.","family":"Eschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1767-6854","authenticated-orcid":false,"given":"Koji","family":"Haratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9288-5285","authenticated-orcid":false,"given":"Marco","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin R.","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7473-9034","authenticated-orcid":false,"given":"John D.","family":"Quadarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-1833","authenticated-orcid":false,"given":"Patrick C.","family":"Gedeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-0401","authenticated-orcid":false,"given":"Jonathan D.","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8506-928X","authenticated-orcid":false,"given":"Michihisa","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4155-5662","authenticated-orcid":false,"given":"Caroline G.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayapatou","family":"Chayawatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-2825","authenticated-orcid":false,"given":"Kenneth","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2287-5663","authenticated-orcid":false,"given":"Cloud P.","family":"Paweletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1974-5921","authenticated-orcid":false,"given":"Prafulla C.","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-413X","authenticated-orcid":false,"given":"Robert T.","family":"Manguso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5988-6828","authenticated-orcid":false,"given":"Ravindra","family":"Uppaluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Barbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"72372_CR1","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson, N. & Ablasser, A. The cGAS\u2013STING pathway and cancer. Nat. Cancer 3, 1452\u20131463 (2022).","journal-title":"Nat. Cancer"},{"key":"72372_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-cancerbio-030518-055636","volume":"3","author":"S Yum","year":"2019","unstructured":"Yum, S., Li, M., Frankel, A. E. & Chen, Z. J. Roles of the cGAS-STING pathway in cancer immunosurveillance and immunotherapy. Annu. Rev. Cancer Biol. 3, 323\u2013344 (2019).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"72372_CR3","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the Type I interferon pathway. Science 339, 786\u2013791 (2013).","journal-title":"Science"},{"key":"72372_CR4","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1158\/0008-5472.CAN-18-1652","volume":"78","author":"JR Baird","year":"2018","unstructured":"Baird, J. R. et al. Evaluation of explant responses to STING ligands: personalized immunosurgical therapy for head and neck squamous cell carcinoma. Cancer Res. 78, 6308\u20136319 (2018).","journal-title":"Cancer Res."},{"key":"72372_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112508","volume":"42","author":"S Miyauchi","year":"2023","unstructured":"Miyauchi, S. et al. Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway. Cell Rep. 42, 112508 (2023).","journal-title":"Cell Rep."},{"key":"72372_CR6","unstructured":"Merck Sharp D. L. Study of ulevostinag (MK-1454) alone or in combination with pembrolizumab (MK-3475) in participants with advanced\/metastatic solid tumors or lymphomas (MK-1454-001). Identifier: NCT03010176, https:\/\/clinicaltrials.gov\/study\/NCT03010176 (2025)."},{"key":"72372_CR7","unstructured":"Chinook Therapeutics, Inc. Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer. Identifier: NCT03937141, https:\/\/clinicaltrials.gov\/study\/NCT03937141?spons=COVERAGE%5BFullMatch%5DEXPANSION%5BNone%5D(%22Chinook%20Therapeutics,%20Inc.%22)&viewType=Table&rank=5 (2022)."},{"key":"72372_CR8","doi-asserted-by":"crossref","unstructured":"Knelson E. H., et al. Activation of tumor-cell STING primes NK-cell therapy. Cancer Immunol. Res.10, 947\u2013961 (2022).","DOI":"10.1158\/2326-6066.CIR-22-0017"},{"key":"72372_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4049\/jimmunol.1601999","volume":"199","author":"B Larkin","year":"2017","unstructured":"Larkin, B. et al. Cutting edge: activation of STING in T cells induces type I IFN responses and cell death. J. Immunol. 199, 397\u2013402 (2017).","journal-title":"J. Immunol."},{"key":"72372_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00573-w","volume":"8","author":"MF Gulen","year":"2017","unstructured":"Gulen, M. F. et al. Signalling strength determines proapoptotic functions of STING. Nat. Commun. 8, 427 (2017).","journal-title":"Nat. Commun."},{"key":"72372_CR11","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1084\/jem.20161674","volume":"214","author":"S Cerboni","year":"2017","unstructured":"Cerboni, S. et al. Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. J. Exp. Med. 214, 1769\u20131785 (2017).","journal-title":"J. Exp. Med."},{"key":"72372_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-16-0104","volume":"4","author":"E Moore","year":"2016","unstructured":"Moore, E. et al. Established T cell\u2013inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade. Cancer Immunol. Res. 4, 1061\u20131071 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"72372_CR13","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1158\/2326-6066.CIR-19-0229","volume":"7","author":"R Falahat","year":"2019","unstructured":"Falahat, R. et al. STING signaling in melanoma cells shapes antigenicity and can promote antitumor T-cell activity. Cancer Immunol. Res. 7, 1837\u20131848 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"72372_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","volume":"9","author":"S Kitajima","year":"2019","unstructured":"Kitajima, S. et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 9, 34\u201345 (2019).","journal-title":"Cancer Discov."},{"key":"72372_CR15","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41586-023-05880-5","volume":"616","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature 616, 806\u2013813 (2023).","journal-title":"Nature"},{"key":"72372_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22572-8","volume":"12","author":"TJ Hayman","year":"2021","unstructured":"Hayman, T. J. et al. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nat. Commun. 12, 2327 (2021).","journal-title":"Nat. Commun."},{"key":"72372_CR17","doi-asserted-by":"crossref","unstructured":"Wang-Bishop, L. et al. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma. J. Immunother. Cancer 8, e000282 (2020).","DOI":"10.1136\/jitc-2019-000282"},{"key":"72372_CR18","doi-asserted-by":"crossref","unstructured":"Tani, T. et al. TREX1 inactivation unleashes cancer cell STING-interferon signaling and promotes anti-tumor immunity. Cancer Discov. 14, 752\u2013765(2024).","DOI":"10.1158\/2159-8290.CD-23-0700"},{"key":"72372_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add8564","volume":"9","author":"L Vornholz","year":"2023","unstructured":"Vornholz, L. et al. Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy. Sci. Adv. 9, eadd8564 (2023).","journal-title":"Sci. Adv."},{"key":"72372_CR20","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.ccell.2022.08.015","volume":"40","author":"S Kitajima","year":"2022","unstructured":"Kitajima, S. et al. MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. Cancer Cell 40, 1128\u20131144.e1128 (2022).","journal-title":"Cancer Cell"},{"key":"72372_CR21","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1158\/2159-8290.CD-20-0913","volume":"11","author":"NR Mahadevan","year":"2021","unstructured":"Mahadevan, N. R. et al. Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity. Cancer Discov. 11, 1952\u20131969 (2021).","journal-title":"Cancer Discov."},{"key":"72372_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37217-1","volume":"14","author":"R Falahat","year":"2023","unstructured":"Falahat, R. et al. Epigenetic state determines the in vivo efficacy of STING agonist therapy. Nat. Commun. 14, 1573 (2023).","journal-title":"Nat. Commun."},{"key":"72372_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/0194599812442037","volume":"147","author":"NP Judd","year":"2012","unstructured":"Judd, N. P., Allen, C. T., Winkler, A. E. & Uppaluri, R. Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. Otolaryngol. Head. Neck Surg. 147, 493\u2013500 (2012).","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"72372_CR24","doi-asserted-by":"crossref","unstructured":"Saulters, E. et al. Differential regulation of the stimulator of interferon genes pathway in human papillomavirus positive and negative head and neck cancers. Cancer Res. Commun. 4, 118\u2013133 (2024).","DOI":"10.1158\/2767-9764.CRC-23-0299"},{"key":"72372_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413\u2013418 (2017).","journal-title":"Nature"},{"key":"72372_CR26","doi-asserted-by":"crossref","unstructured":"Baumgartner, C. K. et al. The PTPN2\/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity. Nature 622, 850\u2013862 (2023).","DOI":"10.3410\/f.742802078.793601193"},{"key":"72372_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1126\/science.aab3291","volume":"350","author":"L Lau","year":"2015","unstructured":"Lau, L., Gray, E. E., Brunette, R. L. & Stetson, D. B. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science 350, 568\u2013571 (2015).","journal-title":"Science"},{"key":"72372_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112258118","volume":"118","author":"H Cheon","year":"2021","unstructured":"Cheon, H., Holvey-Bates, E. G., McGrail, D. J. & Stark, G. R. PD-L1 sustains chronic, cancer cell\u2013intrinsic responses to type I interferon, enhancing resistance to DNA damage. Proc. Natl. Acad. Sci. USA 118, e2112258118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72372_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","volume":"8","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W. et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 8, 196\u2013215 (2018).","journal-title":"Cancer Discov."},{"key":"72372_CR30","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1039\/C8LC00322J","volume":"18","author":"AR Aref","year":"2018","unstructured":"Aref, A. R. et al. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip 18, 3129\u20133143 (2018).","journal-title":"Lab Chip"},{"key":"72372_CR31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1158\/2326-6066.CIR-23-1093","volume":"12","author":"E Toufektchan","year":"2024","unstructured":"Toufektchan, E. et al. Intratumoral TREX1 induction promotes immune evasion by limiting type I IFN. Cancer Immunol. Res. 12, 673\u2013686 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"72372_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1083\/jcb.131.3.631","volume":"131","author":"JA Lorenzen","year":"1995","unstructured":"Lorenzen, J. A., Dadabay, C. Y. & Fischer, E. H. COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus. J. Cell Biol. 131, 631\u2013643 (1995).","journal-title":"J. Cell Biol."},{"key":"72372_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ymeth.2013.08.020","volume":"65","author":"S Bussi\u00e8res-Marmen","year":"2014","unstructured":"Bussi\u00e8res-Marmen, S. et al. Characterization of PTPN2 and its use as a biomarker. Methods 65, 239\u2013246 (2014).","journal-title":"Methods"},{"key":"72372_CR34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/1078-0432.CCR-16-1237","volume":"23","author":"JF Liu","year":"2017","unstructured":"Liu, J. F. et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin. Cancer Res. 23, 1263\u20131273 (2017).","journal-title":"Clin. Cancer Res."},{"key":"72372_CR35","doi-asserted-by":"publisher","first-page":"20063","DOI":"10.1073\/pnas.1906431116","volume":"116","author":"T Xia","year":"2019","unstructured":"Xia, T., Yi, X. M., Wu, X., Shang, J. & Shu, H. B. PTPN1\/2-mediated dephosphorylation of MITA\/STING promotes its 20S proteasomal degradation and attenuates innate antiviral response. Proc. Natl. Acad. Sci. USA 116, 20063\u201320069 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72372_CR36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2111003119","volume":"119","author":"G Berger","year":"2022","unstructured":"Berger, G. et al. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. Proc. Natl. Acad. Sci. USA 119, e2111003119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72372_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/0008-5472.CAN-11-1831","volume":"72","author":"NP Judd","year":"2012","unstructured":"Judd, N. P. et al. ERK1\/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 72, 365\u2013374 (2012).","journal-title":"Cancer Res."},{"key":"72372_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/1078-0432.CCR-19-1351","volume":"26","author":"L Zhou","year":"2020","unstructured":"Zhou, L., Mudianto, T., Ma, X., Riley, R. & Uppaluri, R. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti\u2013PD-1 resistance in head and neck cancer. Clin. Cancer Res. 26, 290 (2020).","journal-title":"Clin. Cancer Res."},{"key":"72372_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004034","volume":"10","author":"L Zhou","year":"2022","unstructured":"Zhou, L. et al. Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. J. Immunother. Cancer 10, e004034 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"72372_CR40","doi-asserted-by":"crossref","unstructured":"Shu, C. et al. Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer. Nat. Commun. 16, 2324 (2025).","DOI":"10.1038\/s41467-025-57297-5"},{"key":"72372_CR41","doi-asserted-by":"publisher","first-page":"9373","DOI":"10.1073\/pnas.0903487106","volume":"106","author":"H Cheon","year":"2009","unstructured":"Cheon, H. & Stark, G. R. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl. Acad. Sci. USA 106, 9373\u20139378 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72372_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11912-023-01361-0","volume":"25","author":"JB Hines","year":"2023","unstructured":"Hines, J. B., Kacew, A. J. & Sweis, R. F. The development of STING agonists and emerging results as a cancer immunotherapy. Curr. Oncol. Rep. 25, 189\u2013199 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"72372_CR43","doi-asserted-by":"publisher","first-page":"e1006985","DOI":"10.1371\/journal.ppat.1006985","volume":"14","author":"A Gangaplara","year":"2018","unstructured":"Gangaplara, A. et al. Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment. PLoS Pathog. 14, e1006985 (2018).","journal-title":"PLoS Pathog."},{"key":"72372_CR44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ccell.2025.12.002","volume":"44","author":"CG Fahey","year":"2026","unstructured":"Fahey, C. G., Cordova, A. F., Gedeon, P. C. & Barbie, D. A. Targeting STING to generate therapeutic anti-tumor immunity. Cancer Cell 44, 260\u2013280 (2026).","journal-title":"Cancer Cell"},{"key":"72372_CR45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10555-017-9694-9","volume":"36","author":"P Zolkind","year":"2017","unstructured":"Zolkind, P. & Uppaluri, R. Checkpoint immunotherapy in head and neck cancers. Cancer Metastasis Rev. 36, 475\u2013489 (2017).","journal-title":"Cancer Metastasis Rev."},{"key":"72372_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ccell.2018.08.009","volume":"34","author":"S Kitajima","year":"2018","unstructured":"Kitajima, S. et al. Overcoming resistance to dual innate immune and MEK inhibition downstream of KRAS. Cancer Cell 34, 439\u2013452.e436 (2018).","journal-title":"Cancer Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72372-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72372-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72372-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:51:00Z","timestamp":1783464660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72372-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72372"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72372-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.B. is is a founder and shareholder in Xsphera Biosciences, a consultant for N of One\/Qiagen and Exo Therapeutics, has received honoraria from Merck, H3 Biomedicine\/Esai, EMD Serono, Gilead Sciences, Abbvie, and Madalon Consulting, and research grants from BMS, Takeda, Novartis, Gilead, and Lilly and Daiichi Sankyo. K.S reported consulting fees from Scholar Rock, AmeriSourceBergen, Guidepoint Global, and Equinox Group, Inc; personal fees for consulting or advisory board participation from Exelixis Inc, Pfizer, Dr. Reddy\u2019s, Fore BioTherapeutics and MedScape; research funding to the institution from Merck and Pfizer; and honoraria from Merck, Gilead, Pri-Med, and BinayTara Foundation. J.D.S declares research support paid to their institution from Merck, BMS, Regeneron, Debiopharm, EMD Serono and Siemens; consulting or participation on a scientific advisory board, and travel fees and payment for lectures from Intragel, Immunitas, Debiopharm, LEK, SIRPant, ACI Clinical, EMD Serono, and Merck KGA; expert witness fees from Burns and White; stock options from Immunitas and Intragel. Patents pending for MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF and Nanobody bioconjugation for immune receptor targeting. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5958"}}